BPGbio, Inc., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak, a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors, as an independent director.
“We are thrilled to welcome Kenin Spivak to the BPGbio Board,” said Daniel Elliott, Executive Chairman of BPGbio. “Kenin’s wealth of experience in multi-disciplinary business fields and expertise in corporate governance are invaluable assets to BPGbio as we as grow our business to the next level by advancing our late-stage therapeutic pipeline and strategic partnerships.”
Mr. Spivak is the founder, chairman and CEO of SMI Group LLC and chairman of its operating units. Prior to SMI Group, Mr. Spivak led multi-national companies with billions of dollars of worldwide sales and operations in more than 30 countries, including serving as CEO of a News Corporation affiliate, a wireless technology company, and distribution companies, principal operating officer of major studio MGM/UA, founding chairman of the Paul Mitchell cosmetology schools, and an officer and director of Merrill Lynch media and entertainment partnerships. He has served as a director of, and advisor to, several healthcare and technology companies.
“BPGbio is greatly accelerating the development of new therapeutics and diagnostics by uniting its pioneering scientific team, the nation’s leading biobank, and cutting-edge AI capabilities,” said Mr. Spivak, adding, “I am honored to join the board and look forward to supporting BPG’s development and commercialization of its late-stage assets.”
Mr. Spivak received A.B., M.B.A. and J.D. degrees from Columbia University, each with honors, completing all three degrees in six years. He is admitted to practice law in California and New York, and holds numerous securities licenses, including Series 24 (general securities principal).
BPGbio’s therapeutic pipeline, developed from the company’s NAi Interrogative Biology® Platform, includes therapeutic candidates being studied for glioblastoma multiforme (GBM) in active phase 2b, pancreatic cancer in phase 2a, epidermolysis bullosa (EB), squamous cell carcinoma (SCC), sarcopenia, solid and liquid tumors, Huntington’s disease, Parkinson’s disease, and diabetes type II. The company’s diagnostic pipeline includes its prostate diagnostic panel pstateDx, as well as tests being developed and validated for the detection of Parkinson’s disease, pancreatic cancer, breast cancer and liver disease.
About BPGbio, Inc.
BPGbio is the leading biology-first AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBio’s novel approach is underpinned by NAI, its proprietary Interrogative Biology Platform, protected by over 450 US and international patents; the world’s largest clinically annotated non-governmental biobank; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way disease is diagnosed and treated. For more information, visit www.bpgbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231113555767/en/